HC Wainwright Analysts Raise Earnings Estimates for CorMedix

CorMedix Inc (NASDAQ:CRMD) – Analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of CorMedix in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.08) per share for the quarter, up from their prior estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is $0.47 per share. HC Wainwright also issued estimates for CorMedix’s Q4 2026 earnings at ($0.06) EPS.

Several other equities research analysts have also recently weighed in on CRMD. Zacks Research raised shares of CorMedix from a “strong sell” rating to a “hold” rating in a research report on Friday. Citizens Jmp reiterated a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th. Weiss Ratings upgraded shares of CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday. Leerink Partners upped their price target on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. Finally, Needham & Company LLC upped their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

CorMedix Price Performance

CorMedix stock opened at $7.91 on Tuesday. The stock has a market cap of $620.48 million, a price-to-earnings ratio of 3.71 and a beta of 1.46. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.97 and a quick ratio of 2.74. CorMedix has a 1 year low of $6.13 and a 1 year high of $17.43. The firm has a 50-day moving average of $7.13 and a two-hundred day moving average of $8.62.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.08. The company had revenue of $127.43 million during the quarter, compared to analysts’ expectations of $104.96 million. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The firm’s quarterly revenue was up 226.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.30 EPS.

Hedge Funds Weigh In On CorMedix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of CorMedix by 13.1% in the fourth quarter. Vanguard Group Inc. now owns 4,499,010 shares of the company’s stock worth $52,323,000 after buying an additional 521,352 shares in the last quarter. Divisadero Street Capital Management LP lifted its stake in shares of CorMedix by 305.7% in the third quarter. Divisadero Street Capital Management LP now owns 288,050 shares of the company’s stock worth $3,350,000 after buying an additional 217,050 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of CorMedix in the third quarter worth about $1,515,000. Hussman Strategic Advisors Inc. lifted its stake in shares of CorMedix by 400.0% in the third quarter. Hussman Strategic Advisors Inc. now owns 315,000 shares of the company’s stock worth $3,663,000 after buying an additional 252,000 shares in the last quarter. Finally, Royce & Associates LP purchased a new position in shares of CorMedix in the third quarter worth about $5,132,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix declared that its board has authorized a stock buyback program on Monday, February 2nd that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 12.3% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.